Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in rats

Brain Research Bulletin

Volumn 121, Issue , 2016, Pages 255-262

  Wan, Dan ^a   Zhou, Yehan ^a   Wang, Ke ^a   Hou, Yongying ^a   Hou, Ruihang ^a   Ye, Xiufeng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

AMPK; ATP; PDEs; Resveratrol; SIRT1; Stroke

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PHOSPHODIESTERASE; RESVERATROL; ROLIPRAM; SIRTUIN 1; ENZYME INHIBITOR; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN TISSUE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BRAIN; BRAIN INFARCTION; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STROKE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BRAIN; BRAIN INFARCTION; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; MALE; NEUROPROTECTIVE AGENTS; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; STROKE;

EID: 84959017298     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2016.02.011     Document Type: Article

References (41)

1. Albani D., Polito L., Batelli S., De Mauro S., Fracasso C., Martelli G., Colombo L., Manzoni C., Salmona M., Caccia S., Negro A., Forloni G. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 2009, 110(5):1445-1456.
2. Aspey B.S.T., Terruli F.L., Harrison M.J. Temporary middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke and reperfusion. Neuropathol. Appl. Neurobiol. 2000, 26(3):232-242.
3. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342.
4. Blander G., Guarente L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73:417-435.
5. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280(17):17187-17195.
6. Charles M.S., Drunalini Perera P.N., Doycheva D.M., Tang J. Granulocyte-colony stimulating factor activates JAK2/PI3K/PDE3B pathway to inhibit corticosterone synthesis in a neonatal hypoxic-ischemic brain injury rat model. Exp. Neurol. 2015, 272:152-159.
7. Chung J.H. Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte 2012, 1(4):256-258.
8. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann. N. Y. Acad. Sci. 2011, 1215:117-122.
9. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(17):7217-7222.
10. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet 2008, 371(9624):1612-1623.
11. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8(10):774-785.
12. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954):191-196.
13. Hsu S.C., Huang S.M., Chen A., Sun C.Y., Lin S.H., Chen J.S., Liu S.T., Hsu Y.J. Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c-jun complex-mediated signaling pathway. Int. J. Biochem. Cell Biol. 2014, 53:361-371.
14. Kulkarni S.S., Canto C. The molecular targets of resveratrol. Biochim. Biophys. Acta 2015, 1852(6):1114-1123.
15. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20(1):84-91.
16. MacDonald E., Van der Lee H., Pocock D., Cole C., Thomas N., VandenBerg P.M., Bourtchouladze R., Kleim J.A. A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia. Neurorehabil. Neural. Repair 2007, 21(6):486-496.
17. Miao Y., Liao J.K. Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev. Neurother. 2014, 14(2):173-185.
18. Miro X., Perez-Torres S., Palacios J.M., Puigdomenech P., Mengod G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 2001, 40(3):201-214.
19. Narayanan S.V., Dave K.R., Saul I., Perez-Pinzon M.A. Resveratrol preconditioning protects against cerebral ischemic injury via nuclear erythroid 2-related factor 2. Stroke 2015, 46(6):1626-1632.
20. Oi N., Yuan J., Malakhova M., Luo K., Li Y., Ryu J., Zhang L., Bode A.M., Xu Z., Li Y., Lou Z., Dong Z. Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene 2015, 34(20):2660-2671.
21. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148(3):421-433.
22. Parsons M.W., Barber P.A., Desmond P.M., Baird T.A., Darby D.G., Byrnes G., Tress B.M., Davis S.M. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann. Neurol. 2002, 52(1):20-28.
23. Pasinetti G.M., Wang J., Ho L., Zhao W., Dubner L. Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochim. Biophys. Acta 2015, 1852(6):1202-1208.
24. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8(2):157-168.
25. Ren J., Fan C., Chen N., Huang J., Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem. Res. 2011, 36(12):2352-2362.
26. Richter W., Menniti F.S., Zhang H.T., Conti M. PDE4 as a target for cognition enhancement. Expert Opin. Ther. Targets 2013, 17(9):1011-1027.
27. Rocha-Gonzalez H.I., Ambriz-Tututi M., Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci. Ther. 2008, 14(3):234-247.
28. Rouse M., Younes A., Egan J.M. Resveratrol and curcumin enhance pancreatic beta-cell function by inhibiting phosphodiesterase activity. J. Endocrinol. 2014, 223(2):107-117.
29. Sun A.Y., Simonyi A., Sun G.Y. The French Paradox and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 2002, 32(4):314-318.
30. Sun A.Y., Sun G.Y. Ethanol and oxidative mechanisms in the brain. J. Biomed. Sci. 2001, 8(1):37-43.
31. Sun A.Y., Wang Q., Simonyi A., Sun G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 2010, 41(2-3):375-383.
32. Takeo S., Niimura M., Miyake-Takagi K., Nagakura A., Fukatsu T., Ando T., Takagi N., Tanonaka K., Hara J. A possible mechanism for improvement by a cognition-enhancer nefiracetam of spatial memory function and cAMP-mediated signal transduction system in sustained cerebral ischaemia in rats. Br. J. Pharmacol. 2003, 138(4):642-654.
33. Tang B.L. Resveratrol is neuroprotective because it is not a direct activator of Sirt1-A hypothesis. Brain Res. Bull. 2010, 81(4-5):359-361.
34. Tresguerres I.F., Tamimi F., Eimar H., Barralet J., Torres J., Blanco L., Tresguerres J.A. Resveratrol as anti-aging therapy for age-related bone loss. Rejuvenation Res. 2014, 17(5):439-445.
35. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., Sun G.Y., Sun A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002, 958(2):439-447.
36. Wang R., Liu Y.Y., Liu X.Y., Jia S.W., Zhao J., Cui D., Wang L. Resveratrol protects neurons and the myocardium by reducing oxidative stress and ameliorating mitochondria damage in a cerebral ischemia rat model. Cell Physiol. Biochem. 2014, 34(3):854-864.
37. Wong R.H., Coates A.M., Buckley J.D., Howe P.R. Evidence for circulatory benefits of resveratrol in humans. Ann. N. Y. Acad. Sci. 2013, 1290:52-58.
38. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430(7000):686-689.
39. Zhang J., Feng X., Wu J., Xu H., Li G., Zhu D., Yue Q., Liu H., Zhang Y., Sun D., Wang H., Sun J. Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by beta-amyloid through activation of SIRT1/Akt1 pathway. Biofactors 2014, 40(2):258-267.
40. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396(6710):474-477.
41. Zhang H.T., Huang Y., Jin S.L., Frith S.A., Suvarna N., Conti M., O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002, 27(4):587-595.